Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01058083

Enrollment

Registered

2010-01-28

Start date

2010-05-31

Completion date

2011-03-31

Last updated

2012-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Brief summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)

Interventions

DRUGBMS-770767

Active, Oral, 15 mg, Daily, 28 days

DRUGPlacebo

Placebo, Oral, 0 mg, daily, 28 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Hypercholesterolemia * Currently taking a stable daily dose of statin therapy * Serum triglyceride level \< 500mg/dl

Exclusion criteria

* History of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accidents within six months prior to entry into the study * Congestive heart failure * Diabetes mellitus * Active liver disease * Impaired renal function * Hepatitis C, B and HIV This list is not inclusive additional information is provided in the protocol

Design outcomes

Primary

Measure	Time frame
Lowering of LDL-C	Within 28 days following dosing

Secondary

Measure	Time frame
Pharmacokinetics (Blood Level) of BMS-770767	Within 28 days following dosing
Pharmacodynamic effects of BMS-770767 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, non-esterified free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)	Within 28 days following dosing

Countries

Australia, Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026